Middle East And Africa Atrial Fibrillation Surgery Market Research Report – Segmented By Surgical Procedure (Catheter Ablation Procedure, Surgical Ablation, Maze procedure), Product & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis From 2026 to 2034
The Middle East and Africa Atrial Fibrillation Surgery Market was valued at USD 0.14 billion in 2024 and is projected to reach USD 0.53 billion by 2033, growing at a CAGR of 16.2% from 2025 to 2033. Increasing prevalence of hypertension, diabetes, and cardiovascular diseases, alongside growing investment in electrophysiology infrastructure, is driving the regional demand for advanced AFib surgical procedures.
Saudi Arabia led the market in 2024 due to strong government initiatives and high procedural volumes.
United Arab Emirates (UAE) is among the fastest-growing markets, supported by public-private collaborations and advanced hospital infrastructure.
Catheter ablation was the dominant surgical procedure segment in 2024, owing to its minimally invasive nature.
Catheter ablation products held the largest share in 2024.
Maze procedure is projected to grow at the fastest rate during the forecast period.
Medtronic, Abbott, and Biosense Webster are key players with strong regional presence.
2024 Market Size: USD 0.14 Billion
2025 Market Size: USD 0.16 Billion
2033 Projected Market Size: USD 0.53 Billion
CAGR (2025–2033): 16.2%
Saudi Arabia: Largest market in 2024
UAE & Israel: Fast-growing markets
The Size of the Middle East and Africa Atrial Fibrillation Surgery Market is valued at USD 0.14 billion in 2024 and is projected to reach USD 0.53 billion by 2033 from USD 0.16 billion in 2025, increasing at a CAGR of 16.2% during the forecast period 2025 to 2033.
The Middle East and Africa Atrial Fibrillation Surgery market refers to the surgical interventions aimed at managing atrial fibrillation (AFib), a common cardiac arrhythmia characterized by irregular and often rapid heartbeats. AFib is associated with increased risks of stroke, heart failure, and cognitive decline, necessitating timely and effective treatment strategies. Surgical options for AFib include catheter ablation, surgical Maze procedures, left atrial appendage closure devices, and hybrid approaches that combine minimally invasive techniques with electrophysiology-guided interventions.
According to the World Heart Federation, non-communicable diseases are rapidly becoming the leading causes of morbidity in the region, with cardiovascular conditions such as AFib gaining prominence due to aging populations, lifestyle changes, and increasing prevalence of metabolic disorders. The Pan African Society of Cardiology highlights that rheumatic heart disease, hypertension, and diabetes remain major contributors to AFib incidence in sub-Saharan Africa, while in the Gulf countries, sedentary lifestyles and obesity have led to rising AFib cases among younger populations.
In response, healthcare systems across the region are expanding their cardiology services and adopting advanced rhythm management protocols. Countries like Saudi Arabia, the UAE, South Africa, and Egypt are investing in electrophysiology infrastructure and physician training programs to enhance AFib diagnosis and treatment capabilities.
One of the primary drivers fueling the Middle East and Africa Atrial Fibrillation Surgery market is the rising incidence of hypertension and diabetes, two key risk factors for developing atrial fibrillation. These chronic conditions contribute significantly to structural heart changes, particularly left atrial enlargement, which predisposes individuals to AFib.
According to the International Diabetes Federation (IDF), diabetes affects over 20% of adults in parts of the Gulf region, with Saudi Arabia and the UAE reporting some of the highest prevalence rates globally. Similarly, as per the World Health Organization (WHO), hypertension affects nearly one in four adults in North Africa and the Middle East, contributing to an increasing burden of AFib-related complications.
In sub-Saharan Africa, where hypertension remains largely undiagnosed and untreated, according to the African Population-based Stroke Study, up to 70% of ischemic strokes were linked to uncontrolled high blood pressure. Given that AFib is a known cause of cardioembolic stroke, addressing this underlying condition through surgical intervention has become a growing priority. With regional health authorities emphasizing early detection and improved cardiovascular care, the demand for atrial fibrillation surgeries is expected to continue its upward trajectory.
Another key driver of the Middle East and Africa Atrial Fibrillation Surgery market is the expansion of electrophysiology (EP) infrastructure and the increasing availability of trained specialists capable of performing complex AFib interventions. Over the past decade, several countries in the region have made significant investments in establishing dedicated EP labs and enhancing cardiac rhythm management capabilities.
These facilities are equipped with advanced mapping systems, enabling precise identification and elimination of abnormal electrical pathways responsible for AFib.
In North Africa, Morocco’s Ministry of Health has partnered with European cardiac societies to train local physicians in ablation techniques, resulting in a 30% increase in AFib procedures since 2021.
Additionally, South Africa’s Groote Schuur Hospital has reported a doubling of AFib interventions in recent years, supported by enhanced diagnostic tools and interventional expertise. As regional governments continue to invest in cardiac infrastructure and workforce development, the capacity for atrial fibrillation surgery is expanding, supporting sustained market growth across both urban and semi-urban centers.
A major restraint affecting the Middle East and Africa Atrial Fibrillation Surgery market is the high cost of AFib procedures, which limits patient access and hampers broader adoption of surgical interventions. Catheter ablation, left atrial appendage closure, and other advanced treatments require expensive disposable components, imaging equipment, and hospital resources, making them financially challenging for many healthcare systems in the region.
In addition, out-of-pocket healthcare expenditure remains high in many African countries, with a notable share of medical costs being borne directly by patients. In Nigeria, a single ablation procedure can cost up to $10,000—an amount beyond the reach of most citizens without insurance coverage.
Even in wealthier Gulf nations, where public healthcare systems provide broader coverage, reimbursement policies for newer AFib interventions remain inconsistent. As per the Saudi Commission for Health Specialties, while basic AFib care is widely covered, advanced surgical treatments often require partial or full patient co-payments, limiting uptake among eligible candidates.
In sub-Saharan Africa, the situation is further compounded by underfunded hospitals and limited procurement of essential consumables.
The shortage of skilled electrophysiologists and the lack of well-established referral networks pose a significant challenge to the growth of the Middle East and Africa Atrial Fibrillation Surgery market. While demand for rhythm management interventions is on the rise, the scarcity of trained professionals remains a critical barrier to widespread treatment adoption.
According to the Pan African Society of Cardiology, there are fewer than 200 practicing electrophysiologists across the entire African continent, with most concentrated in South Africa, Egypt, and Tunisia. In contrast, developed regions like Europe and North America have thousands of specialists serving smaller patient populations, highlighting the disparity in service availability.
In the Gulf, although expatriate specialists help bridge the gap, the lack of standardized training programs for local physicians creates long-term sustainability concerns.
Apart from these, weak referral systems prevent patients from accessing timely specialist care. Without a strong pipeline of trained professionals and efficient referral mechanisms, market expansion remains constrained across much of the region.
A major opportunity for the Middle East and Africa Atrial Fibrillation Surgery market lies in government-led initiatives focused on cardiovascular disease prevention and structured management of arrhythmias. Several national health authorities have recognized the growing burden of AFib and are implementing targeted programs to improve screening, diagnosis, and treatment access.
In Saudi Arabia, Vision 2030 includes specific objectives for reducing cardiovascular mortality, with over SAR 20 billion (USD 5.3 billion) allocated toward building new cardiac centers and equipping existing hospitals with advanced electrophysiology capabilities. The Ministry of Health has also introduced standardized guidelines for AFib management, promoting early diagnosis and appropriate surgical intervention when indicated.
These policy-driven efforts not only enhance early detection but also create a favorable environment for the expansion of atrial fibrillation surgical services, offering substantial growth potential for market players seeking to expand their footprint in the region.
The growing adoption of minimally invasive techniques and technological advancements presents a significant opportunity for the Middle East and Africa Atrial Fibrillation Surgery market. Innovations such as contact force sensing catheters, robotic-assisted ablation, and cryoballoon technology have improved procedural success rates, reduced complication risks, and shortened recovery times, making these interventions more attractive to both physicians and patients.
Hospitals in Kuwait, Bahrain, and Oman are increasingly adopting 3D electroanatomical mapping systems to enhance procedural precision and optimize outcomes.
In South Africa, according to Groote Schuur Hospital, there has been a doubling of AFib ablation cases since 2020, attributed to better access and collaboration with international medical societies. Meanwhile, Cairo University Hospital has integrated robotic-assisted ablation into routine practice, improving procedural consistency and expanding treatment options for persistent AFib patients.
With continued investment in advanced technologies and physician education, the use of minimally invasive atrial fibrillation surgeries is expected to grow, providing a strong foundation for future market expansion across the region.
A major challenge facing the Middle East and Africa Atrial Fibrillation Surgery market is the fragmented nature of healthcare systems and disparities in access to specialized cardiac care. While certain urban centers have developed robust cardiology services, rural and low-resource areas continue to face significant gaps in diagnostic and treatment capabilities.
According to the World Health Organization (WHO), less than 10% of rural populations in Sub-Saharan Africa have access to specialized cardiac care, forcing patients to travel long distances or forego treatment entirely. In Yemen and Sudan, political instability and economic constraints have severely curtailed the availability of cardiac surgical facilities.
Even in relatively developed markets like Egypt and Jordan, disparities exist between private and public sector capabilities. The Egyptian Ministry of Health acknowledges that public hospitals often face shortages of essential equipment and consumables needed for AFib interventions.
In the Gulf, while healthcare access is more consistent, regulatory inefficiencies and inconsistent referral pathways can delay timely surgical interventions. Until healthcare delivery becomes more standardized and accessible across the region, disparities will continue to hinder market growth.
Lack of public awareness and late presentation of AFib cases represent a critical challenge for the Middle East and Africa Atrial Fibrillation Surgery market. Many patients remain undiagnosed until they experience severe complications such as stroke or heart failure, limiting the effectiveness of surgical interventions and increasing healthcare costs.
According to the African Stroke Organization, up to 60% of AFib-related strokes in sub-Saharan Africa occur in patients who were unaware of their condition before the event. This indicates a significant gap in early detection and preventive care.
Educational campaigns targeting both healthcare professionals and the general population remain limited, contributing to poor disease recognition. Without widespread community-level education and integration of AFib screening into national health programs, the potential for surgical treatment remains underutilized, posing a persistent hurdle to market growth in the region.
The catheter ablation procedure segment dominated the Middle East and Africa Atrial Fibrillation Surgery market, capturing an estimated 68.5% of the regional share in 2024. This dominance is attributed to its minimally invasive nature, high success rates in treating drug-refractory AFib, and increasing adoption across urban medical centers.
In Egypt, as per the Cairo University Hospital, catheter ablation utilization has risen by 40% over the past three years, driven by improved access to mapping technologies and physician training programs. Similarly, Groote Schuur Hospital in South Africa has seen a doubling of AFib ablation cases due to enhanced diagnostic capabilities and growing awareness among cardiologists.
These factors collectively reinforce the leadership of the catheter ablation procedure segment in the regional market.
The Maze procedure is projected to grow at the highest CAGR of 9.2%, reflecting its increasing use in patients undergoing concomitant cardiac surgeries such as valve replacement or coronary artery bypass grafting (CABG). While traditionally reserved for surgical candidates, recent modifications—such as minimally invasive approaches and robotic-assisted techniques—have enhanced its appeal and procedural efficiency.
Additionally, advancements in energy sources—such as cryoablation and radiofrequency systems—have made the Maze procedure more accessible and safer for broader application. As reported by Sheba Medical Center in Israel, hybrid Maze techniques have improved long-term rhythm control, making them an attractive option for patients who are not responsive to catheter-based interventions.
With growing surgeon expertise and integration into multidisciplinary cardiac care pathways, the Maze procedure is emerging as a rapidly expanding component of the Middle East and Africa Atrial Fibrillation Surgery landscape.
The Catheter Ablation product segment held the largest market share of 65.7%, driven by widespread adoption of this minimally invasive technique for managing atrial fibrillation. Its dominance stems from technological advancements, increasing physician familiarity, and growing patient preference for less invasive treatments.
According to the Gulf Heart Association, the number of catheter ablation procedures performed in the GCC has grown by over 30% since 2020, largely due to improvements in 3D mapping systems and contact force sensing technology. Medtronic and Abbott have expanded their distribution networks across the region, ensuring a steady supply of essential components such as irrigated tip catheters and intracardiac echocardiography tools.
In South Africa, some hospitals have adopted AI-driven navigation platforms, enhancing precision and procedural outcomes. With continued investment in training and equipment procurement, the catheter ablation segment remains the most dominant in the Middle East and Africa Atrial Fibrillation Surgery market.
The Surgical Ablation product segment is expected to grow at the fastest CAGR of 9.5%, fueled by rising demand for concomitant AFib treatment during open-heart procedures and the increasing adoption of standalone minimally invasive surgical options. Unlike traditional open-chest Maze procedures, modern surgical ablation techniques—such as thoracoscopic ablation and hybrid approaches—are gaining traction due to reduced invasiveness and improved success rates.
The King Faisal Specialist Hospital in Riyadh has recorded a 28% annual increase in surgical ablation procedures since 2022, citing improved postoperative rhythm control as a key factor.
In Israel, Sheba Medical Center has pioneered hybrid ablation strategies combining catheter and surgical techniques, reporting a significant improvement in long-term sinus rhythm maintenance compared to catheter-only interventions. So, with growing acceptance among cardiothoracic surgeons and enhanced support from device manufacturers, the surgical ablation segment is experiencing rapid expansion across the Middle East and select African markets.
Saudi Arabia held the largest market share of 28.5% in the Middle East and Africa Atrial Fibrillation Surgery market, driven by strategic investments in cardiology infrastructure and policy-driven cardiovascular disease management programs.
According to the Saudi Heart Association, the Kingdom has witnessed a 35% increase in AFib procedures between 2020 and 2024, supported by standardized clinical guidelines and physician training initiatives.
Moreover, partnerships with global cardiology societies have enabled knowledge transfer and hands-on training for local physicians. Hospitals like King Faisal Specialist Hospital and Prince Sultan Cardiac Center have become regional hubs for complex AFib interventions, offering state-of-the-art catheter and surgical ablation services. With continued funding for cardiac research and digital health integration, Saudi Arabia maintains its position as the leading contributor to the Middle East and Africa Atrial Fibrillation Surgery market.
The United Arab Emirates is emerging as one of the fastest-growing contributors due to its world-class healthcare infrastructure and proactive national health strategies. The UAE’s Ministry of Health has integrated AFib screening into primary care settings, enhancing early detection and guiding appropriate treatment decisions.
Private healthcare providers such as the Cleveland Clinic Abu Dhabi and Dubai Healthcare City have played a pivotal role in expanding access to advanced rhythm management solutions.
The UAE government has also mandated continuing medical education for cardiologists, ensuring up-to-date knowledge on AFib treatment protocols. Besides, the country benefits from streamlined regulatory pathways that facilitate quicker adoption of new technologies and devices. With growing emphasis on non-communicable disease prevention and a strong presence of multinational device manufacturers, the UAE continues to strengthen its position in the atrial fibrillation surgery market, positioning itself as a regional leader in cardiac rhythm management.
Israel contributes majorly to the MEA atrial fibrillation surgery market, despite its small geographical size, due to its reputation as a global hub for cardiac innovation and high clinical adoption rates. The country leads in AFib treatment advancements, with some of the highest per capita ablation and surgical intervention rates in the region.
Israeli hospitals such as Sheba Medical Center and Tel Aviv Sourasky Medical Center are pioneers in hybrid AFib interventions, combining catheter and surgical approaches for optimal outcomes.
Israeli-developed technologies—including real-time cardiac mapping systems and AI-enhanced navigation tools—are widely used across the Middle East and North Africa, further reinforcing the country’s influence on regional AFib care.
Egypt represents a growing contributor to the Middle East atrial fibrillation surgery market, with increasing institutional capacity and physician expertise in complex rhythm disorders. Historically reliant on pharmacological management, the country has recently intensified efforts to adopt interventional AFib treatments, particularly in academic medical centers.
According to the Egyptian Heart Rhythm Society, the number of AFib procedures performed annually has risen by 28% since 2020, driven by improved access to ablation technologies and structured physician training programs. The Egyptian Ministry of Health has also taken steps toward integrating AFib screening into hypertension and diabetes clinics, recognizing the link between metabolic diseases and arrhythmias. Collaborations with international device manufacturers have facilitated the procurement of ablation systems and mapping technologies, enhancing procedural availability.
With rising awareness, improved infrastructure, and government-backed initiatives, Egypt is gradually transforming into a regional center for atrial fibrillation surgical interventions, supporting broader market expansion across North Africa.
South Africa is serving as the primary hub for advanced cardiac rhythm management in sub-Saharan Africa. Despite resource constraints in the public sector, private hospitals in Cape Town, Johannesburg, and Durban have significantly expanded their AFib treatment capabilities in recent years.
The country benefits from a relatively well-established cardiac care infrastructure and trained electrophysiologists, although disparities persist between private and public healthcare delivery models. With growing emphasis on early detection and improved treatment access, South Africa continues to serve as a regional leader in AFib surgical interventions, setting a precedent for neighboring African nations seeking to enhance arrhythmia care.
Key market participants dominating the Middle East and Africa Atrial Fibrillation Surgery Market profiled in the Report are Cardiofocus, Inc., nContact, Inc., Biosense Webster, Inc., Medtronic, Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Articure, Inc., Cardima, Inc., and Biotronik SE & Co.
The competition in the Middle East and Africa Atrial Fibrillation Surgery market is intensifying as global medical device companies seek to expand their influence in the region. Established players such as Medtronic, Abbott, and Biosense Webster dominate due to their broad product portfolios, technological leadership, and strong clinical engagement. These companies actively collaborate with regional hospitals and academic centers to drive adoption and build long-term relationships with cardiologists and electrophysiologists.
At the same time, emerging competitors—both multinational and regional—are entering the space with cost-effective solutions and localized service models. Local distributors and joint ventures are becoming increasingly important as they enable foreign manufacturers to navigate regulatory landscapes and supply chain challenges more efficiently.
Competition is also shaped by pricing strategies, with some firms offering bundled packages to make AFib treatments more accessible in emerging markets. Additionally, the rise of mobile cardiac units and telehealth-based AFib monitoring is reshaping how care is delivered, presenting new opportunities for market growth.
As awareness increases and healthcare systems evolve, the competitive landscape is expected to become more dynamic, requiring continuous adaptation and localized strategies from market participants.
Medtronic plc
Medtronic is a global leader in cardiac rhythm management and plays a pivotal role in the Middle East and Africa Atrial Fibrillation Surgery market. The company offers a comprehensive portfolio of ablation catheters, mapping systems, and implantable devices that support both catheter and surgical interventions for AFib. Medtronic actively collaborates with leading hospitals and academic institutions across the region to enhance clinical adoption and physician training. Its presence is particularly strong in Saudi Arabia, the UAE, and South Africa, where it supports the expansion of electrophysiology labs and promotes best practices in AFib treatment.
Abbott Laboratories
Abbott contributes significantly to the regional atrial fibrillation surgery market through its advanced cardiac mapping and ablation technologies. The company’s EnSite system is widely used in major hospitals across the Gulf and North Africa, enabling precise diagnosis and targeted treatment of complex arrhythmias. Abbott invests heavily in education and capacity building by sponsoring training programs and fellowships for local physicians. These efforts are aimed at improving procedural outcomes and increasing access to high-quality AFib care across both public and private healthcare settings in the Middle East and Africa.
Biosense Webster (a Johnson & Johnson Company)
Biosense Webster is a key participant in the Middle East and Africa Atrial Fibrillation Surgery market, offering state-of-the-art ablation and navigation systems tailored for AFib treatment. The company has expanded its regional footprint through strategic distributor partnerships and technical support programs designed to improve procedural efficiency and physician expertise. Biosense Webster’s focus on innovation and clinical collaboration has enabled hospitals in the Gulf and North Africa to adopt next-generation ablation techniques, strengthening its position as a preferred provider of AFib intervention tools in the region.
One major strategy employed by key players in the Middle East and Africa Atrial Fibrillation Surgery market is strategic partnerships and collaborations with regional healthcare institutions, including teaching hospitals, cardiology societies, and government health agencies. These alliances facilitate knowledge transfer, clinical training, and improved access to advanced AFib treatment technologies.
Another key approach is investment in physician training and certification programs, aimed at addressing the shortage of skilled electrophysiologists in the region. Companies sponsor workshops, hands-on labs, and international exchange programs to equip local doctors with the expertise required for complex AFib interventions.
Lastly, market localization and distribution network expansion play a crucial role in strengthening market presence. Multinational firms are forming agreements with regional distributors and establishing direct sales teams to ensure a reliable supply of ablation systems, mapping tools, and implantable devices across urban and semi-urban healthcare centers in the Middle East and Africa.
This research report on the Middle East &Africa Atrial Fibrillation Surgery Market has been segmented and sub-segmented into the following categories.
By Surgical Procedure
By Product
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region